Mabtech-Revvity Webinar

Online | Oct 22

Event Details

Sample quality is data quality: how pre-analytical variables shape your data

Join us for our upcoming webinar with Revvity where we discuss and highlight the importance of proper sample handling in clinical studies and trials.

  • When: 6pm AEDT | Wednesday October 22, 2025
  • Duration: 45 minutes
  • Can’t make it live? This webinar will be recorded.

You’ll learn about:

The common pitfalls and their effects in logistical planning around samples as well look at how delays in sample processing affect common functional cell-based assays like FluoroSpot and flow cytometry.

  • Proper cell handling techniques
  • Common pitfalls in sample logistics and their consequences
  • Cell functionality assessment methods and sensitivities

Don’t miss this opportunity to strengthen your workflow and ensure your research is built on high-quality, reproducible results.

Presenters
 

Tyler Sandberg holds a PhD in vaccine immunology from the Karolinska Institutet, where he used FluoroSpot to evaluate human vaccine- and infection-specific B cell responses. Tyler joined Mabtech in 2022 and has been working as the Product Manager for ELISpot, FluoroSpot and EYRAplex.

Jonathan Dodd is a Senior Manager of Assay Development at Revvity, based in Oxford, UK. With over four years at the company, he leads innovative assay design and development initiatives, with a particular focus on TB diagnostics. Trained as a T cell immunologist, Jonathan specialises in respiratory disease, bringing deep expertise in cellular immunology and translational assay development to support cutting-edge research and clinical applications. His work bridges fundamental immunology with applied technologies, driving advancements in diagnostic solutions for complex diseases.

Host

Jens Gertow holds a PhD in transplantation immunology from the Karolinska Institute, where he also did a postdoc at the Department of Medicine. Joined Mabtech in 2015, was appointed CCO in 2018, and moved into the role of CMO in 2025.

On this page